1. Clinical Characteristics and Outcomes of Patients with Culture-Negative Pyogenic Spondylitis according to Empiric Glycopeptide Use
- Author
-
Jin-Sung Kim, Jung-Woo Hur, Yoon Hee Jeon, Yong Dae Lee, Young Hoon Kim, Kyeong Sik Ryu, Kee Yong Ha, and Youn Jeong Kim
- Subjects
medicine.medical_specialty ,Culture ,Pyogenic spondylodiscitis ,Glycopeptide ,Group B ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Interquartile range ,Antibiotics ,Internal medicine ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Prospective cohort study ,Spondylitis ,0303 health sciences ,medicine.diagnostic_test ,030306 microbiology ,business.industry ,medicine.disease ,Infectious Diseases ,Erythrocyte sedimentation rate ,Population study ,Original Article ,business - Abstract
BACKGROUND The optimal choice of antibiotics is challenging in culture-negative pyogenic spondylitis (PS). The empiric use of glycopeptides is suggested depending on various risk factors, although clinical data are sparse. This study aimed to analyze the clinical characteristics and outcomes of patients with culture-negative PS and evaluate the effect of empiric glycopeptide use on clinical outcomes in these patients. MATERIALS AND METHODS Data on the characteristics, treatment, and outcomes of 175 patients diagnosed with PS were retrospectively obtained from the electronic database of a tertiary referral hospital from 2009 to 2016. Patients with negative culture results were grouped by the duration of glycopeptide treatment: glycopeptide therapy
- Published
- 2019